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Abstract 
 
Endogenous cholesterol acts as a precursor of testosterone and other steroids hormones, this study was conducted to 
evaluate if there is a counterproductive effect associated with inhibition of cholesterol biosynthesis pathway specially in high 
doses and the degree of these effects in normal male rats. Forty eight adult Wistar rats divided into four groups, the first is 
control while the remaining three groups were treated with simvastatin (cholesterol biosynthesis inhibitor) in doses of 25, 50 
and 100 mg.kg
-1 respectively. Serum samples were observed at the baseline then every fifteen days while tissue samples were 
observed at day 30 and 60. Results of statistic refered to a significant decrease (p≤ 0.05) in serum total cholesterol and 
triglycerides (by 24 and 49% ± 3) respectively, also serum testosterone was significantly decreased (by 71% ± 2) in all groups 
compared to control after thirty and sixty days. The activity of alanine aminotransferase was increased (57% ± 3) versus to 
aspartate  aminotransferase.  Liver  cholesterol  was  significantly  decreased  (by  72%  ±  2)  while  testicular  cholesterol  was 
decreased except the group of 100 mg.kg
-1 which in turns to elevate (61% ± 4), in addition also there was a decrease in body 
weight gain percentage neither the weights of liver nor testis was affected. In conclusion, the inhibition of denovo pathway of 
cholesterol biosynthesis negatively affects testosterone level in addition to cholesterol concentration in the tissues, body weight 
gain and alanine aminotransferase with no successful compensatory mechanism as related with testosterone level.  
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Introduction 
 
Cholesterol is present in the tissues and plasma either as 
free or cholesteryl esters in which a little more than half of 
body  total  cholesterol  arises  by an endogenous synthesis 
and the remainder supplied via receptor mediated uptake 
from  circulating  lipoproteins  (1),  virtually  all  tissues 
containing  nucleated  cells  are  capable  of  cholesterol 
synthesis from acetyl Co- A. The enzyme 3- Hydroxy 3- 
methyl glutaryl Coenzyme- A (HMG Co-A) reductase, is a 
principle regulatory (rate limiting) step and a site of action 
of most effective cholesterol lowering drugs (2, 3). 
Androgens are a group of steroid hormones that include 
testosterone which is the main hormone responsible for the 
male reproductive activity (3), steroidogenesis is performed 
in  gonads  and  adrenal  from  cholesterol  precursor. 
Testicular androgens are synthesized in the interstitial tissue 
by  the  Leydig  cells  using  cholesterol  delivered  by  the 
transport  protein  StAR  to  the  inner  membrane  of 
mitochondria  where chain cleavage enzyme P450 scc. in 
turn to results in pregnenolone, this action is promoted by 
leutinizing hormone (LH) (4), testosterone formation from 
pregnenolone  required  five  enzymes  localized  in 
microsomal portion of rat testis, although there was a traces 
of testosterone synthesized in the adrenal (3). 
Several studies refered to that the inhibition of denovo 
cholesterol  biosynthesis  pathway  leads  to  a  significant 
reduction  in  the  steroidogenesis  in  the  WHHL  rabbits 
females  (5)  and  women's  ovary  (6).  In  males,  it  was 
demonstrated  that  testosterone  biosynthesis  requires  a 
continuous  cholesterol  supply  (7)  so  the  inhibition  of 
cholesterol biosynthesis pathway may results in a decline in 
plasma testosterone which may lead to a marked decrease 
in  the  fertility  index  and  sperm  cell  count  (8),  also  the 
supplementation  of  hen's  diet  with  HMG  Co-A  inhibitor 
(0.03 or 0.05%) may lead to an increase in the incidence of 
unfertilized eggs and decreased hatchability (9). 
Although  studies  have  examined  the  effect  of  HMG 
Co-A reductase inhibitors on gonadal function, but there 
was  no  univocal  results  (10,  11)  because  some  authors 
found that statins did not produce biological adverse effects 
on steroidogenesis in males (7, 12, 13) and in females (14). 
Simvastatin  is  an  efficient  HMG  Co-  A  reductase 
inhibitor  which  is  widely  used  in  most  countries  as  a 
hypocholesterolemic drug (15).    
The aim of this study was to investigate the dose related 
potential  effects  that  is  affecting  the  normal  testicular 
secretion  of  testosterone  arising  from  the  inhibition  of 
denovo  cholesterol  biosynthesis  pathway  in  the  normal 
male rats using simvastatin, also to inspect it's effect on 
some  liver  enzymes  activity  and  testicular  content  of 
cholesterol.  
 
Materials and methods 
 
ِ Animals and diet: Forty eight Wistar rats (3- months old) 
with weight range about 255 ± 15 g obtained from animal 
house,  College  of  Veterinary  Medicine  were  divided 
randomly into four groups (twelve rats each) and brought in 
room  temperature  with  12:12  light:dark  cycle.  Diet 
ingredients supplied in order to meets the rats nutritional 
and  physiological  requirements  (16),  diet  was  moistened 
with  distilled  water  and  formed  in  the  shape  of  pellets 
which  dried  in  an  electric  oven  at  55  C°,  prepared  diet 
check up was done for insurance emptiness of cholesterol 
by qualitative test of Salkowski (17). 
Simvastatin:  SIMVOR  20  mg  (RANBAXY  laboratories 
limited,  India)  was  used  as  a  form  of  suspension  in  the 
treatment of rats by oral gavage. 
Experimental  design:  The  study  includes  the  following 
four groups: 
- Group one regarded as control which treated with methyl 
cellulose as a vehicle for sixty days. 
- Groups two, three and four treated with simvastatin 25, 50 
and 100 mg. kg
-1 BW. respectively by oral gavage for sixty 
days. 
At the day 30 of treatment, six rats of each group were 
sacrificed  by  separation  of  cervical  spinal  cord  and 
specimens collected (serum and tissues) in addition to the 
detection of organ's weights (liver and testes) whereas the 
remaining rats were sacrificed in the same manner at the 
60
th day. 
Specimens  collection:  Blood  specimens  were  collected 
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a.m. after about 12 hour of fasting from retroocular vein 
(18)  by  using  capillary  tubes.  After  coagulation  blood 
samples were centrifuged (1000 ×g at 4 C°) for 15 min. 
then serum was collected and maintained in deep freezing. 
Liver  and  testes  were  dissected,  immersed  with  ice cold 
saline  (0.9%  NaCl),  dried  on  filter  paper,  weighed  and 
frozen for subsequent analysis.  
Weight gain calculation: Body weight gain was calculated 
every fifteen days throughout the period of the experiment, 
percentage of weight gain was calculated by subtracting the 
initial weight (g) from the recent weight then divided on the 
initial weight × 100. 
Organ weight: Percentage of organ's weight was calculated 
at the end of experiment by dividing the weight of organ (g) 
on the ultimate weight of the animal (g) × 100.  
Serum biochemical tests: Fasting total cholesterol TC and 
triglycerides TG were assayed enzymatically using specific 
kits  manufactured  from  Fabricant  Biolabo  SA,  France. 
Total  testosterone  was  assayed  by  specific 
radioimmunoassay  RIA  (Immunotech,  France).  Serum 
transaminases  activity  was  assayed  using  specific  kits 
manufactured from BioMerieux sa, France. 
Tissue total cholesterol: TC in the liver and testis were 
assayed  by  extracting  the  total  lipids  in  the  tissue  by 
chloroform/ methanol (2:1 v/v) (19), the chloroform phase 
was collected and evaporated on water bath (45 C°) and 
lipids were redissolved in 200 µl ethanol (98%) then total 
cholesterol assayed spectrophotometrically (20). 
Statistical  analysis:  Quantitative  data  were  subjected  to 
two  way  analysis  of  variance  according  to  (21).  Arcsine 
transformation were used for data expressed as percentages. 
Means differences were statistically compared according to 
Duncan multiple range test (22) using computer program, 
statistical package for social sciences (SPSS). 
 
Results 
 
There  was  significant  decrease  (p≤  0.05)  in  serum 
cholesterol  (mg.  100  ml
-1)  among  simvastatin-  treated 
groups  compared  with  baseline  (Table  1).  This  decrease 
was more distinct in groups 50 and 100 mg. kg
-1 since day 
30 and since day 45 as considered with the group 25 mg. 
kg
-1. 
Triglycerides (mg. 100 ml
-1) also decreased during the 
treatment  in  the  groups  received  the  three  doses  of 
simvastatin  (Table  2),  triglycerides  concentration  was 
nearly 1- fold lower in simvastatin- treated versus control at 
the  days  30,  45  and  60  with  no  significant  differences 
among treated groups except the value of the day 30 which 
illustrated significant difference (p≤ 0.05) between groups 
of 25 and 50 mg. kg
-1 on one arm and group of 100 mg. kg
-1 
on the other arm which showed the least value. 
 
Table  1:  Effect  of  cholesterol  biosynthesis  inhibitor 
(simvastatin) on serum cholesterol level (mg/100 ml).  
 
Period of treatment (day)  Groups 
0  15   30   45   60  
Control  74.06  
± 
10.48  
e 
70.07 
± 
1.14 
de 
72.83 
± 
1.14 
de 
70.51 
± 
2.04 
de 
69.65 
± 
2.12 
de 
Simvastatin  
(25 mg/kg) 
70.13  
± 
1.13  
de 
70.71 
± 
0.81 
de 
66.04 
± 
1.82 
c-e 
60.24 
± 
0.78 
a-c 
56.01 
± 
1.21 
ab 
Simvastatin  
(50 mg/kg
 ) 
 
70.66  
± 
0.99 
de 
71.42 
± 
1.93 
de 
53.66 
± 
1.84 
a 
53.97 
± 
1.11 
a 
52.36 
± 
2.11 
a 
Simvastatin  
(100 mg/kg
 ) 
71.48  
± 
0.86 
de 
64.06 
± 
1.71 
b-d 
53.64 
± 
2.28 
a 
56.36 
± 
1.74 
ab 
57.89 
± 
1.77 
a-c 
-  Different letters in the same column or in the same row 
refers to a significant difference (p≤ 0.05). 
-  Values are expressed as mean ± SE. 
 
Table  2:  Effect  of  cholesterol  biosynthesis  inhibitor 
(simvastatin) on serum triglycerides (mg/100 ml)  
 
Period of treatment (day)  Groups 
  0  15   30   45   60  
Control  79.56 
 ± 
1.78 
d 
81.21 
± 
2.29 
de 
81.04 
± 
1.02 
de 
87.14 
± 
2.54 
e 
87.31 
± 
2.54 
e 
Simvastatin  
(25 mg/kg) 
82.32 
 ± 
2.79 
de 
82.09 
± 
1.66 
de 
47.50 
± 
1.58 
c 
41.65 
± 
1.51 
a-c 
43.39 
± 
3.67 
a-c 
Simvastatin  
(50 mg/kg) 
 
80.84 
 ± 
2.53 
de 
78.15 
± 
2.07 
d 
44.68 
± 
1.82 
bc 
40.54 
± 
1.16 
ab 
38.45 
± 
1.40 
ab 
Simvastatin  
(100 mg/kg) 
84.90 
 ± 
1.93 
de 
81.07 
± 
1.39 
de 
37.96 
± 
1.94 
a 
40.42 
± 
0.80 
ab 
42.88 
± 
2.80 
a-c 
-  Different letters in the same column or in the same row 
refers to a significant difference (p≤ 0.05). 
-  Values are expressed as mean ± SE. 
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Treated  animals  maintained  good  aspartate 
aminotransferase (AST) activity control (U. L
-1) throughout 
the study (Table 3) with no differences as compared with 
control group whereas the effect of simvastatin caused a 
persistent  elevation  in  the  activity  of  alanine 
aminotransferase (ALT) (U. L
-1) as table (4) refers to in a 
dose response manner from the baseline starting from day 
30 in 25 and 50 mg. kg
-1 groups and from day 15 in group 
of 100 mg. kg
-1. Evident that ALT activity was decreased 
just in group of 50 mg. kg
-1 at day 45 however the value 
returned to rise at day 60. 
 
Table  3:  Effect  of  cholesterol  biosynthesis  inhibitor 
(simvastatin) on aspartate aminotransferase activity (U/L). 
 
Period of treatment (day)  Groups 
 
   
 
0  15   30   45   60  
Control  57.84  
± 
0.66  
b-e 
58.04 
± 
0.89 
b-e 
57.80 
± 
2.41 
b-e 
57.73 
± 
1.30 
b-e 
58.27 
± 
1.08 
c-e 
Simvastatin  
(25 mg/kg) 
57.01  
± 
1.62 
b-e 
58.56 
± 
1.39 
c-e 
57.75 
± 
1.14 
b-e 
56.95 
± 
0.72 
b-e 
57.78 
± 
0.95 
b-e 
Simvastatin  
(50 mg/kg) 
 
53.22  
± 
0.57 
ab 
55.42 
± 
1.06 
a-c 
56.72 
± 
2.09 
b-d 
61.98 
± 
3.44 
de 
60.80 
± 
0.34 
de 
Simvastatin  
(100 mg/kg) 
51.65  
± 
0.72 
a 
55.49 
± 
1.59 
a-c 
57.07 
± 
1.62 
b-e 
60.45 
± 
0.52 
de 
61.31 
± 
0.84 
de 
-  Different letters in the same column or in the same row 
refers to a significant difference (p≤ 0.05). 
-  Values are expressed as mean ± SE. 
 
As clearly evidenced from (Figure 1), treatment with 
an efficient 3- hydroxy 3- methyl glutaryl Co- A (HMG Co- 
A)  reductase  inhibitor  significantly  (p≤  0.05)  lowered 
serum  total  testosterone  for  all  three  treated  groups 
compared with control in a dose related fashion for both 30 
and 60 days of trials. 
Table  (5)  summarizes  the  effect  of  cholesterol 
biosynthesis inhibition on liver and testicular of cholesterol. 
Liver,  cholesterol  declined  after  30  days  of  treatment 
significantly  (p≤  0.05)  in  the  three  treated  groups  in  a 
parallel mode as compared with control, the values obtained 
after  60  days  of  treatment  were  further  declined  with 
approximately 1- fold decrease compared with values of 30 
days not related with dose, in contrast testicular cholesterol 
elevated in both groups of 50 and 100 mg. kg
-1 at day 30, 
this elevation reversed to a drop below the values of 30
th 
day of treatment showing the least value in the group of 50 
mg. kg
-1 and the higher value in the group of 100 mg. kg
-1. 
 
Table  4:  Effect  of  cholesterol  biosynthesis  inhibitor 
(simvastatin) on alanine aminotransferase activity (U/L). 
 
Period of treatment (day)  Groups 
 
   
 
0  15   30   45   60  
Control  41.33  
± 
0.64 
ab  
40.83 
± 
0.85 
ab 
43.50 
± 
1.38 
a-d 
41.81 
± 
0.61 
a-c 
42.65 
± 
0.52 
a-d 
Simvastatin  
(25 mg/kg) 
40.82  
± 
1.10 
ab 
40.87 
± 
0.50 
ab 
46.0 
± 
1.93 
cd 
44.78 
± 
1.35 
b-d 
53.54 
± 
0.65 
e 
Simvastatin  
(50 mg/kg) 
 
39.81  
± 
1.35 
a 
41.52 
± 
0.69 
ab 
51.11 
± 
2.87 
e 
46.42 
± 
1.12 
d 
65.35 
± 
1.58 
g 
Simvastatin  
(100 mg/kg) 
40.02  
± 
0.35 
a 
51.30 
± 
1.28 
e 
63.12 
± 
3.28 
fg 
60.88 
± 
0.81 
f 
66.31 
± 
0.84 
g 
-  Different letters in the same column or in the same row 
refers to a significant difference (p≤ 0.05). 
-  Values are expressed as mean ± SE. 
 
Table  5:  Effect  of  cholesterol  biosynthesis  inhibitor 
(simvastatin) on tissue cholesterol level (mg/g wet tissue) 
 
Period of treatment  
day 30
th  day 60
th 
 
 
Groups  Liver  Testis  Liver  Testis 
Control  33.85 ± 
2.43c 
13.0 ± 
1.29bc 
33.06 ± 
2.18c 
13.37 ± 
1.20bc 
Simvastatin  
(25 mg/kg) 
 
20.45 ± 
0.32b 
14.25 ± 
0.92c 
11.91 ± 
0.71a 
10.51 ± 
0.61ab 
Simvastatin  
(50 mg/kg) 
 
22.17 ± 
0.59b 
21.47 ± 
1.44e 
9.12 ± 
1.29a 
8.57 ± 
0.70a 
Simvastatin  
(100 mg/kg) 
 
19.29 ± 
1.77b 
24.49 ± 
1.01f 
12.06 ± 
2.75a 
18.14 ± 
0.16d 
 
-  Different letters in the same column or in the same row 
refers to a significant difference (p≤ 0.05). 
-  Values are expressed as mean ± SE. 
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 - Different letters refer to a significant difference (p≤ 0.05). 
 - Values are expressed as mean±SE.  
 
 
Percentage of liver weight increased significantly (p≤ 
0.05)  in  group  received  the  dose  50  mg. kg
-1 versus the 
groups of control, 25 and 100 mg. kg
-1 after 30 days of 
treatment  (figure  2),  values  obtained  after  60  days  of 
treatment  demonstrated  an  approach  in  values  with  no 
significant differences among the three simvastatin- treated 
groups as well as the control one. 
 
Figure (2). Effect of cholesterol biosynthesis inhibitor 
(simvastatin) on liver weight percentage.
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- Different letters refer to a significant difference (p≤ 0.05). 
 - Values are expressed as mean± SE. 
 
Percentage  of  testis  weight  exhibited  an  increase  in 
groups of 50 and 100 mg. kg
1 compared with control with 
no differences among the three treated groups after 30 days 
of treatment. 60 Days of treatment indicated that there was 
more  noticeable  results  that  revealed  an  increase  in 
percentage of testis weight of the group 25 mg. kg
-1 and 
decrease in that of group 100 mg. kg
-1 with respect to 30
th 
day values. Both the values of the groups 25 and 50 mg. kg
1 
are  significantly  rise  up  regarding  with  both  groups  of 
control  and  100  mg.  kg
-1  which  there  were  interrelating 
values (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Different letters refer to a significant difference (p≤ 0.05). 
 - Values are expressed as mean± SE. 
 
 
As clearly evident (figure 4), mean body weight gain 
percentage began to diminish since the day 30 of treatment 
in  an  analogue  mode  for  the  three  simvastatin-  treated 
groups opposed to control, this finite weight gain continued 
in the same fashion throughout the period of experiment till 
the day 60 of the treatment. Also to which must be noticed 
that the falling in the weight gain percentages was inversely 
related to the dose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Different letters refer to a significant difference (p≤ 0.05). 
Values are expressed as mean± SE. 
 
Figure (1). Effect of cholesterol biosynthesis 
inhibitor (simvastatin) on serum testosterone.
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Figure (3). Effect of cholesterol biosynthesis inhibitor (simvastatin) on 
testis weight percentage.
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Figure (4). Effect of cholesterol biosynthesis inhibitor (simvastatin) on 
body weight gain percentage.
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Discussion 
  
It  is  not  surprising  that  the  inhibition  of  cholesterol 
biosynthesis  process  results  significant  decrease  in  the 
serum total cholesterol as the data suggests (table 1), these 
observations are fully agree with the previously reported 
observations of Adah and Ormiston and their teams who 
detected a significant reduction in serum total cholesterol 
after three weeks of treatment with simvastatin (23, 24), 
also Friberg and co- investigators conformed these results 
through an in vitro study on rat granulosa cells (25), despite 
some  papers  disagree  with  these  findings  which  did  not 
found significant changes in serum total cholesterol of rats 
(26, 27). The hypocholesterolemic potency of statins has 
been elucidated by inhibiting activity of the rate limiting 
enzyme, 3- hydroxy 3- methyl glutaryl Co- A reductase in 
the cholesterol biosynthesis pathway leading to decrease in 
both free and cholesteryl esters (28).  
Statins related compounds increases and stabilizes the 
low density lipoproteins cholesterol (LDL-c) receptors gene 
expression through triggering the up regulation of the LDL-
c  receptors  mRNA  in  rat's  hepatocytes  (29), through the 
effect of serum cholesterol level on the sterol regulating 
element- binding protein which controls the specific gene 
expression participating in the cholesterol cellular uptake 
mechanism and metabolism leading to a drop in it's plasma 
level  (3),  all  the  former  results  are  corresponding  and 
explaining the observations of the present study relating to 
serum total cholesterol level.  
In  view  of  the  decreased  triglycerides  concentration 
caused  by  simvastatin  oral  doses  (table  2),  our  findings 
somewhat resemble those of a previous studies in human 
(30), in normal female rats (31) and in alcohol- treated rats 
(32). 
The  reduction  in  serum  triglycerides  level  may  be  a 
consequence  of  the  action  of  HMG  Co-A  reductase 
inhibitors  which  inhibits  lipase  activity  probably  by 
decreasing lipase mRNA (31), another theory elucidates the 
reason of decreased serum triglycerides level was because 
of the inhibitory action of simvastatin on the cytoplasmic 
form  of  the  enzyme  diacylglycerol  acyltransferase  which 
catalyzes the final reaction in the synthesis of triglycerides 
in the rat liver microsome (33) furthermore the effect of 
treatment  with  high  doses  of  statins  markedly  decrease 
plasma very low density lipoproteins cholesterol (VLDL-c) 
and the related triglycerides level (34) but in comparison 
with results of the present study, which shown that the high 
dose  (100  mg.  kg
-1)-  triglycerides  responsive  level  was 
statistically similar with other two doses (25 and 50 mg. kg
-
1) since the day 45 of treatment. 
Data  scorer  as  considered  with  aspartate 
aminotransferase  (AST)  and  alanine  aminotransferase 
(ALT) are partially fit with previous studies related with 
ALT activity (table 4) which shown an increment in normal 
human serum (35), normal rabbits and rats ALT at a high 
dose for two weeks of treatment (36, 37) Despite our data 
disapprove last studies as related with raised AST activity 
in them which continue insignificant in the present study 
(table 3). 
Some  experiments  explained  several  possible 
mechanisms for statin- associated high ALT activity with 
the  occurrence  of  skeletal  myopathy  which  have  been 
proposed  recently,  depletion  of  secondary  metabolic 
intermediates and induction of apoptosis and alteration of 
chloride channel conductance within myocytes (38). 
The  significant  decrease  in  serum  total  testosterone 
shown in figure (1) are some kind identical with previously 
reported data by Azzarito and co- investigators who found 
that  the  treatment  of  hypercholesterolemic  men  with 
simvastatin  for  twelve  months  resulted  a  moderate 
reduction  in  serum  testosterone  (7)  also  statin  treatment 
inhibited the testosterone production by 25 % in rats and in 
women with polycystic ovary syndrome (39), on the other 
aspect  studies  refer  to  that  serum  testosterone  was 
unchanged by statin treatment in human males (10, 13) and 
in normal rats (23). 
Some  studies  found  a  reverse  results  as  related  to 
testosterone  level  which  in  turns  to  increase  during  the 
treatment with statins (40), these results disagree with the 
observations of the present study. 
The  cholesterol  biosynthesis  inhibitor  was  found  to 
suppress  gonadal  steroidogenesis  which  includes 
androstenediol  and  testosterone  through  it's  known 
inhibitory effect on HMG Co-A reductase activity but an 
additional  mechanism was demonstrated by affecting the 
later  steps  of  testicular  steroidogenesis  by  selectively 
inhibition of 17- ketosteroidoxidoreductase which catalyze 
the  conversion  of  dehydroepiandrosterone  and 
androstenedione  to  androstenediol  and  testosterone 
respectively  (41),  another  study  found  that  simvastatin 
caused  a  significant  decrease  in  the  testosterone  6-  beta 
hydroxylation in the cytochrom P450 of human hepatocytes 
(42)  as  well  as  the  evidence  of  that  statins  to  reduce 
receptor mediated uptake of cholesterol in the gonads for 
steroidogenesis (43) and suppress the lutenizing hormone 
(LH) level which controls on a part of steroidogenesis (23). 
All the observations in text above assures and explains 
the results of the present study as related with testosterone 
level  and  the  dose  related  testosterone  reduction  is fully 
associated with reduced serum total cholesterol as a normal 
result of testosterone precursor depletion. 
The decline in liver cholesterol caused by inhibition of 
cholesterol biosynthesis pathway (table 6), agree with Hou 
and his team who recorded 50% reduction in tissue's total 
cholesterol  after  cholesterol  biosynthesis  inhibition  in 
normal mice (44). Simvastatin- treated female rats shown a 
sharp increase in cholesteryl esters in the liver microsome 
as a result of the inhibitory action of simvastatin on hepatic Iraqi Journal of Veterinary Sciences, Vol. 23, No.1, 2009 (5-12)  
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lipase  mRNA  expression  (31)  versus  to  the  data  of  the 
present study which demonstrated a decline in liver total 
cholesterol. 
It  has  been  reported  that  the  relatively  selective 
inhibition  of  liver  cholesterol  synthesis  by  statin 
compounds  might  be  due  to  the  existence  of  a  specific 
uptake  mechanism  mediated  by  the  Na
+-  independent 
multispecific  anion  transporter  systems  (38)  whereas  the 
surprising  increase  levels of total cholesterol in testis of 
group received 100 mg. kg
-1 after sixty days of treatment 
are  elucidated  as  a  result  of  reduction  of  high  density 
lipoproteins  cholesterol  (HDL-c)  binding  proteins  (HB1 
and HB2) with no effect on serum cholesterol concentration 
(26), now it is known that HMG Co-A reductase synthesis 
and activity increase following their competitive inhibition 
by  statins  leading  to  increase  in  rate  of  cholesterol 
biosynthesis  in  tissues  (45)  in  addition  to  the  high  dose 
statin treatment of rats rises enzyme acyl Co- A: cholesterol 
acyl transferase mRNA level (34). 
A recent in vitro study found that the apolipoprotein E 
incorporated in rat HDL-c has a high affinity for LDL-c 
receptors so suggested that rat Leydig cells can use HDL-c 
as a substitute to regulate testicular steroidogenesis via an 
apolipoprotein pathway (42), also this elevation in testicular 
cholesterol content may be due to the notable ability of rat's 
Leydig cells for autorecovary in a progressive manner, this 
event was associated with a striking proliferation of smooth 
endoplasmic  reticulum  and  peroxysomes,  this  hypothesis 
discussed  that  these  morphologic  alteration  are  the 
counterpart  of  enhanced  newly  synthesis  of  HMG  Co-A 
reductase  that  is  a  mode  of  compensatory  response  of 
Leydig cells aimed to maintaining an adequate production 
of cholesterol despite of the competitive inhibition of HMG 
Co-A  reductase  by  statins  (46).  This  compensation  of 
cholesterol  level  in  the  testis  did  not  resulted  in  up 
regulation of testosterone production probably due to the 
relative short- term duration of treatment. 
The  relative  stable  values  in  liver  weight  percentage 
relative to whole body weight among the three simvastatin- 
treated groups compared with control (figure 2) throughout 
the duration of treatment is in agreement status with results 
published by Adah and co- investigators in different species 
of  male  animals  which  demonstrated  there  were  no 
influence  of  cholesterol  biosynthesis  inhibition  on  the 
weights of liver and reproductive organs (12, 23) however 
testis  weight  percentages  are  significantly  increased  in 
groups of 25 and 50 mg. kg
-1 after sixty days of treatment 
(figure 3) without satisfying interpreting. 
The dose related drop in body weight gain percentage 
relative  to  initial  body  weight  described  in  figure  (4)  is 
against the observations of Adah and his co- investigators 
in animals treated with simvastatin for sixty-five days (12, 
23), in the same time, normal mice received statin family 
shown a reduction in body weight possibly due to decreased 
food consumption (34). Another theory tried to explain the 
reduced  weight  gain  as  a  result  of  less  pronounced  bile 
acids biosynthesis produced by the action of HMG Co-A 
reductase inhibitors progressively with dose doubling (47). 
In conclusion, there were a direct proportion between 
serum  total  cholesterol  and  testicular  concentration  of 
cholesterol  in  normal  rats, negatively reflected on serum 
testosterone and triglycerides, in addition to decreased body 
weight gain and increased serum alanine aminotransferase 
activity. Furthermore there was a compensatory mechanism 
for  decreased  level  of  cholesterol  in  the  testis  without 
affecting on dependant testosterone.  
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